Evidence map›Paper›PMID 42589724›Full record

ArticleInternational journal of molecular sciences2026

Correction: Nishimura et al. Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated Angiogenesis.

Naoki Nishimura, Kosuke Kaji, Norihisa Nishimura, Junichi Hanatani, Tatsuya Nakatani, Masafumi Oyama, Akihiko Shibamoto, Yuki Tsuji, Koh Kitagawa, Shinya Sato and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Naoki NishimuraDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Kosuke KajiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Norihisa NishimuraDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0000-0002-6295-3283
Junichi HanataniDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0009-0001-9174-2477
Tatsuya NakataniDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0009-0008-5703-016X
Masafumi OyamaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Akihiko ShibamotoDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Yuki TsujiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.
Koh KitagawaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0000-0001-5794-1512
Shinya SatoDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0000-0003-3049-3443
Tadashi NamisakiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.ORCID 0000-0002-3158-5318
Satoru TamaokiMedical Affairs Department, ASKA Pharmaceutical Co., Ltd., Minato-ku 108-8532, Tokyo, Japan.
Hitoshi YoshijiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8521, Nara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication [...].

Identifiers

PMID42589724
PMCPMC13466705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.